| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10806743 | BRAINTREE LABS | Method of administering lactitol to reduce plasma concentration of lactitol |
May, 2037
(13 years from now) | |
Pizensy is owned by Braintree Labs.
Pizensy contains Lactitol.
Pizensy has a total of 1 drug patent out of which 0 drug patents have expired.
Pizensy was authorised for market use on 12 February, 2020.
Pizensy is available in for solution;oral dosage forms.
Pizensy can be used as method of treating chronic idiopathic constipation in adult patients..
Drug patent challenges can be filed against Pizensy from 13 February, 2024.
The generics of Pizensy are possible to be released after 12 May, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2025 |
Drugs and Companies using LACTITOL ingredient
NCE-1 date: 13 February, 2024
Market Authorisation Date: 12 February, 2020
Treatment: Method of treating chronic idiopathic constipation in adult patients.
Dosage: FOR SOLUTION;ORAL
More Information on Dosage
PIZENSY family patents
